Investigating PLCG2 as a treatment target for Alzheimer's Disease
Validating PLCG2 as a target for the treatment of Alzheimer's Disease through cell biology and pharmacological tools
This study is looking at how certain changes in a gene called PLCG2 might affect the risk of developing Alzheimer's Disease, using special cells to see how these changes influence brain cell behavior, which could lead to new ways to treat the disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10996419 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific genetic variants of the PLCG2 gene influence Alzheimer's Disease (AD) risk and protection. By using human stem cell-derived microglia-like cells, the study aims to explore how these variants affect cellular signaling pathways related to AD. The researchers will employ advanced techniques like mass spectrometry to analyze the molecular changes induced by PLCG2 modulation. This approach could help identify new therapeutic strategies for treating Alzheimer's Disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are at risk for or diagnosed with Alzheimer's Disease.
Not a fit: Patients under the age of 65 or those without any genetic predisposition to Alzheimer's Disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target the underlying mechanisms of Alzheimer's Disease.
How similar studies have performed: Previous research has shown promise in targeting genetic variants for Alzheimer's treatment, indicating that this approach could be a valuable avenue for further exploration.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Bedford, Logan — Indiana University Indianapolis
- Study coordinator: Bedford, Logan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.